These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4648492)

  • 21. Structure-based design, synthesis, and A-site rRNA cocrystal complexes of functionally novel aminoglycoside antibiotics: C2" ether analogues of paromomycin.
    Hanessian S; Szychowski J; Adhikari SS; Vasquez G; Kandasamy P; Swayze EE; Migawa MT; Ranken R; François B; Wirmer-Bartoschek J; Kondo J; Westhof E
    J Med Chem; 2007 May; 50(10):2352-69. PubMed ID: 17458946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmocodynamics of lividomycin in renal failure.
    Fillastre JP; Humbert G; Daufresne MF; Dubois D; Leroy A
    Proc Eur Dial Transplant Assoc; 1973; 10(0):547-50. PubMed ID: 4802558
    [No Abstract]   [Full Text] [Related]  

  • 23. Syntheses of 5''-deoxylividomycin A and its amino derivative.
    Yamamoto H; Kondo S; Maeda K; Umezawa H
    J Antibiot (Tokyo); 1972 Aug; 25(8):487-8. PubMed ID: 4648493
    [No Abstract]   [Full Text] [Related]  

  • 24. Syntheses of 6', 5'', 6''''-triamino-6', 5'', 6''''-trideoxylividomycin A and 6', 5''-dideoxylividomycin B.
    Kondo S; Yamamoto H; Iinuma K; Maeda K; Umezawa H
    J Antibiot (Tokyo); 1976 Oct; 29(10):1134-6. PubMed ID: 1049661
    [No Abstract]   [Full Text] [Related]  

  • 25. Letter: Kanamycin phosphotransferase. I. Mechanism of cross resistance between kanamycin and lividomycin.
    Umezawa H; Yamamoto H; Yagisawa M; Kondo S; Takeuchi T
    J Antibiot (Tokyo); 1973 Jul; 26(7):407-11. PubMed ID: 4592805
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapeutic effects of lividomycin in the retreatment for pulmonary tuberculosis patients].
    Yamamoto M; Fukuhara T; Aoyagi T
    Kekkaku; 1973 Apr; 48(4):121-7. PubMed ID: 4721804
    [No Abstract]   [Full Text] [Related]  

  • 27. [Studies on the therapeutic effects of lividomycin in retreatment for pulmonary tuberculosis (author's transl)].
    Donomae I; Fujita S; Gomi J; Hibino S; Horai Z
    Kekkaku; 1974 Jan; 49(1):21-7. PubMed ID: 4827206
    [No Abstract]   [Full Text] [Related]  

  • 28. Aminoglycoside antibiotics: synthesis of 5''-amino-5''-deoxyneomycin and 5''-amino-5''-deoxyparomomycin.
    Hanessian S; Massé R; Capmeau ML
    J Antibiot (Tokyo); 1977 Oct; 30(10):893-6. PubMed ID: 591451
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacokinetics of lividomycin, aminkacin and sisomicin in patients with chronic renal insufficiency].
    Leroy A; Oksenhendler G; Fillastre JP; Humbert G
    J Urol Nephrol (Paris); 1977 Sep; 83(9):738-41. PubMed ID: 243544
    [No Abstract]   [Full Text] [Related]  

  • 30. Semisynthetic aminoglycoside antibiotics. III. New deoxy derivatives of paromomycin.
    Battistini C; Cassinelli G; Franceschi G; Arcamone F; Mazzoleni R
    J Antibiot (Tokyo); 1981 Feb; 34(2):240-2. PubMed ID: 7298513
    [No Abstract]   [Full Text] [Related]  

  • 31. [Isolation and substrate specificity of neomycin (paromomycin)--phosphotransferase from Actinomyces fradiae, a producer of neomycin].
    Demina AS; Griaznova NS; Ganelin VL; Sazykin IuO
    Antibiotiki; 1977 Dec; 22(12):1066-70. PubMed ID: 596851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the serum half life of lividomycin in uraemic patients.
    Humbert G; Fillastre JP; Daufresne MF; Dubois D; Leroy A
    Curr Ther Res Clin Exp; 1974 Mar; 16(3):232-8. PubMed ID: 4206730
    [No Abstract]   [Full Text] [Related]  

  • 33. Studies on lividomycin. I. In vitro antibacterial activities of LVDM against clinical isolates of Mycobacterium tuberculosis.
    Shimizu T
    Jpn J Antibiot; 1974 Dec; 27(6):766-74. PubMed ID: 4142798
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical evaluation of lividomycin (LVDM) on acute gonorrhea (author's transl)].
    Terao E
    Jpn J Antibiot; 1974 Oct; 27(5):671-4. PubMed ID: 4218272
    [No Abstract]   [Full Text] [Related]  

  • 35. [Minimum inhibitory concentration of lividomycin for gonococci and its clinical effect in gonorrhea (author's transl)].
    Onoda Y; Tsunematsu Y; Kamei K
    Jpn J Antibiot; 1974 Aug; 27(4):471-4. PubMed ID: 4215906
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative pharmacokinetics of lividomycin, amikacin and sisomicin in normal subjects and in uraemic patients.
    Leroy A; Humbert G; Oksenhendler G; Fillastre JP
    J Antimicrob Chemother; 1976 Dec; 2(4):373-81. PubMed ID: 1052072
    [No Abstract]   [Full Text] [Related]  

  • 37. Aminoglycoside 3'-phosphotransferase III, a new phosphotransferase. Resistance mechanism.
    Umezawa Y; Yagisawa M; Sawa T; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1975 Nov; 28(11):845-53. PubMed ID: 53228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lividomycin: microbiological activity in vitro and in vivo].
    Vitali C; Ripa S; Viticchi C
    Ann Sclavo; 1973; 15(3):329-46. PubMed ID: 4776388
    [No Abstract]   [Full Text] [Related]  

  • 39. Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections.
    Berkov-Zrihen Y; Herzog IM; Feldman M; Sonn-Segev A; Roichman Y; Fridman M
    Bioorg Med Chem; 2013 Jun; 21(12):3624-31. PubMed ID: 23602621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antibacterial activity of lividomycin against several bacteria isolated from clinical specimens].
    Yamaguchi M; Mishashi S
    Jpn J Antibiot; 1972 Dec; 25(6):336-9. PubMed ID: 4198941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.